Seres Therapeutics Provides Corporate Updates and Financial Results

On January 9, 2025, Seres Therapeutics, Inc. (NASDAQ: MCRB) released significant updates regarding its recent achievements and financial standing. The company shared details from its preliminary financial results, new translational biomarker findings from the SER-155 Phase 1b clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), as well as corporate developments. The translational […]

Leave a Reply

Your email address will not be published.

Previous post Cohort (LON:CHRT) Stock Price Crosses Above 200-Day Moving Average – Here’s Why
Next post Rep. Lloyd Doggett Purchases Shares of The Coca-Cola Company (NYSE:KO)